Status:
UNKNOWN
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Sohag University
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
Brief Summary
Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Ni...
Detailed Description
Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor with 5-year survival rate as low as 9%. It is the seventh leading cause of cancer-related de...
Eligibility Criteria
Inclusion
- Patients with pancreatic ductal adenocarcinoma who underwent surgery.
Exclusion
- Patients received pre-operative chemotherapy or radiotherapy.
- Patients with insufficient clinical data.
- Specimens with extensive necrosis
- Tiny specimens which are insufficient for accurate diagnosis.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05228808
Start Date
February 1 2022
End Date
December 1 2022
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Sohag University
Sohag, Egypt